Comparative Pharmacology
Head-to-head clinical analysis: DAPZURA RT versus SEGLUROMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPZURA RT versus SEGLUROMET.
DAPZURA RT vs SEGLUROMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective estrogen receptor degrader (SERD) and antagonist; binds to estrogen receptor alpha (ERα), induces its degradation, and inhibits estrogen-dependent growth.
SEGLUROMET is a fixed-dose combination of ertugliflozin and metformin. Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Metformin decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
20 mg orally once daily
Initial: 2.5 mg ertugliflozin/1000 mg metformin twice daily. Titrate based on efficacy and tolerability. Maximum: 5 mg ertugliflozin/2000 mg metformin twice daily.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (sufficient for once-daily dosing in most patients; prolonged in renal impairment).
Ertugliflozin: terminal half-life ~16.6 hours (range 10-20 h), supporting once daily dosing. Metformin: terminal half-life ~6.2 hours (range 4-8.7 h) in patients with normal renal function; prolonged in renal impairment.
Primarily renal: 70-80% unchanged in urine; biliary/fecal excretion accounts for 10-15% as metabolites.
Segluromet (ertugliflozin and metformin) is primarily excreted via renal (ertugliflozin: ~40.9% unchanged in urine; metformin: ~90% unchanged in urine) and fecal/biliary routes (ertugliflozin: ~50.2% in feces as parent and metabolites; metformin: <1% in bile).
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor/Biguanide Combination